Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

Siponimod significantly reduced the risk of confirmed disability progression (CDP), worsening in cognitive processing speed (CPS), relapses, and magnetic resonance imaging (MRI) measures of brain atrophy and inflammation versus placebo in secondary progressive multiple sclerosis (SPMS) patients in t...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Multiple sclerosis Ročník 28; číslo 10; s. 1591
Hlavní autori: Cree, Bruce Ac, Arnold, Douglas L, Fox, Robert J, Gold, Ralf, Vermersch, Patrick, Benedict, Ralph Hb, Bar-Or, Amit, Piani-Meier, Daniela, Rouyrre, Nicolas, Ritter, Shannon, Kilaru, Ajay, Karlsson, Goeril, Giovannoni, Gavin, Kappos, Ludwig
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England 01.09.2022
Predmet:
Atrophy
Azetidines
Benzyl Compounds
Humans
Multiple Sclerosis - drug therapy
Multiple Sclerosis, Chronic Progressive - drug therapy
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Recurrence
confirmed cognitive worsening
cortical gray matter
S1P modulator
secondary progressive multiple sclerosis
Confirmed disability progression
siponimod
ISSN:1477-0970, 1477-0970
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Siponimod significantly reduced the risk of confirmed disability progression (CDP), worsening in cognitive processing speed (CPS), relapses, and magnetic resonance imaging (MRI) measures of brain atrophy and inflammation versus placebo in secondary progressive multiple sclerosis (SPMS) patients in the Phase 3 EXPAND study. The aim of this study was to assess long-term efficacy and safety of siponimod 2 mg/day from the EXPAND study including the extension part, up to > 5 years. In the open-label extension part, participants receiving placebo during the core part were switched to siponimod (placebo-siponimod group) and those on siponimod continued the same treatment (continuous siponimod group). Continuous siponimod reduced the risk of 6-month CDP by 22% (hazard ratio (HR) (95% confidence interval (CI)): 0.78 (0.66-0.92)  = 0.0026) and 6-month confirmed worsening in CPS by 23% (HR (95% CI): 0.77 (0.65-0.92)  = 0.0047) versus the placebo-siponimod group. Sustained efficacy on annualized relapse rate, total and regional brain atrophy, and inflammatory disease activity was also observed. No new, unexpected safety signals for siponimod were identified over the long term. The sustained efficacy and consistent long-term safety profile of siponimod up to > 5 years support its clinical utility for long-term treatment of SPMS. Benefits in the continuous siponimod versus placebo-siponimod group highlight the significance of earlier treatment initiation. NCT01665144.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1477-0970
1477-0970
DOI:10.1177/13524585221083194